GM-3009
Pharmaceutical compound
From Wikipedia, the free encyclopedia
GM-3009 is a κ-opioid receptor (KOR) agonist and noribogaine analogue which is under development for the treatment of opioid-related disorders.[1][3][2] Its route of administration is unspecified.[1]
| Clinical data | |
|---|---|
| Other names | GM3009 |
| Routes of administration | Unspecified[1] |
| Drug class | κ-Opioid receptor agonist[2] |
The drug is a highly potent agonist of the human KOR, with an affinity (Ki) of 0.9 nM or 87.3 nM depending on the radioligand and an EC50 of 0.8 nM.[2] In contrast to noribogaine, it did not show pro-arrhythmic effects in fresh human ventricular cardiomyocytes ex vivo.[2] GM-3009 produces antinociceptive effects and dose-dependently reduces oxycodone self-administration in rodents.[2]
It is being developed by Gilgamesh Pharmaceuticals.[1][3] As of June 2024, it is in the preclinical research stage of development.[1][3] The exact chemical structure of GM-3009 does not yet appear to have been disclosed.[1] However, it is known to be an "oxa-iboga" derivative.[4] Oxa-ibogaine analogues have notably been patented and studied by Dalibor Sames and colleagues, with Sames being a co-founder of Gilgamesh Pharmaceuticals.[5][6][7]